kanglemycin-a and Tuberculosis

kanglemycin-a has been researched along with Tuberculosis* in 1 studies

Other Studies

1 other study(ies) available for kanglemycin-a and Tuberculosis

Article	Year
Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism. Nature communications, 2018, 10-08, Volume: 9, Issue:1 Rifamycin antibiotics (Rifs) target bacterial RNA polymerases (RNAPs) and are widely used to treat infections including tuberculosis. The utility of these compounds is threatened by the increasing incidence of resistance (Rif Topics: Aminobenzoates; Antibiotics, Antitubercular; Bacteria; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Bacterial; Humans; Hydroxybenzoates; Metagenomics; Molecular Structure; Mutation; Mycobacterium tuberculosis; Rifampin; Rifamycins; Soil Microbiology; Tuberculosis	2018

Article

Year

Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism.

Nature communications, 2018, 10-08, Volume: 9, Issue:1

Rifamycin antibiotics (Rifs) target bacterial RNA polymerases (RNAPs) and are widely used to treat infections including tuberculosis. The utility of these compounds is threatened by the increasing incidence of resistance (Rif

Topics: Aminobenzoates; Antibiotics, Antitubercular; Bacteria; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Bacterial; Humans; Hydroxybenzoates; Metagenomics; Molecular Structure; Mutation; Mycobacterium tuberculosis; Rifampin; Rifamycins; Soil Microbiology; Tuberculosis

2018